<DOC>
	<DOCNO>NCT01816048</DOCNO>
	<brief_summary>The purpose study ass whether NaF PET/CT scan use evaluate treatment response bone metastases subject prostate cancer treat investigational drug , TAK-700 .</brief_summary>
	<brief_title>NaF Positron Emission Tomography/Computed Tomography ( PET/CT ) Imaging Assess Treatment Responsiveness TAK-700 Patients With Castrate Resistant Prostate Cancer ( CRPC ) With Bone Metastasis</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Sodium Fluoride</mesh_term>
	<mesh_term>Fluorides</mesh_term>
	<mesh_term>Listerine</mesh_term>
	<criteria>Male patient 18 year old Voluntary write consent Histologically proven adenocarcinoma prostate Evidence radiographic bone metastasis May receive prior chemotherapy metastatic disease , prior chemotherapy requirement eligibility Eastern Cooperative Oncology Group performance status 02 Serum testosterone level less equal 50 ng/dL Has undergone orchiectomy plan continue receive gonadotropin release hormone ( GnRH ) analogue therapy Adequate organ function measure screen laboratory value specify protocol Must agree use appropriate contraceptive prior study procedure , duration study participation 4 month last dose TAK 700 Must able lie flat great equal 30 minute PET/CT image Screening calculated ejection fraction great equal 50 % multigated radionuclide angiography ( MUGA ) scan Echocardiogram Received Strontium89 , Samarium153 , radioisotope within 3 month registration history allergic reaction attribute compound similar sodium fluoride F18 ( NaF ) history seizure disorder Known history brain metastasis Concurrent treatment herbal product within 7 day study entry Received radiotherapy less equal 4 week prior registration Known hypersensitivity TAK700 relate compound Prior therapy treatment metastatic castrate resistant prostate cancer androgen biosynthesis inhibitor androgen signal pathway inhibitor : enzalutamide ( MDV3100 ) , abiraterone , ketoconazole , aminoglutethimide Current bladder neck outlet obstruction Current spinal cord compression Current bilateral hydronephrosis History adrenal insufficiency History myocardial infarction , unstable symptomatic ischemic heart disease , ongoing arrhythmia ( grade 2 ) , thromboembolic event , cardiac condition within 6 month prior first dose study drug . Uncontrolled high blood pressure Known history human immunodeficiency virus ( HIV ) infection , hepatitis B , hepatitis C Major surgery less equal 4 week first dose study drug Serious infection less equal 2 week first dose study drug Known gastrointestinal ( GI ) disease GI procedure could interfere oral absorption tolerance TAK700 , include difficulty swallowing capsule</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>prostate , prostate cancer</keyword>
</DOC>